Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

GU Cancers 2025 | Implementing liquid biopsy in multiple aspects of urothelial carcinoma

Gillian Vandekerkhove • 15 Feb 2025

GU Cancers 2025

Bladder Cancer Genitourinary Cancer

Gillian Vandekerkhove, PhD, Vancouver Prostate Centre, Vancouver, Canada, discusses the potential for liquid biopsy in every stage of urothelial carcinoma management. Trials display prospective use in molecular residual disease to guide adjuvant therapies in muscle-invasive bladder cancer (MIBC). FDA-approved predictive biomarkers and tumour tissue analysis in clinical trials have shown benefits in precision medicine. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.